Evidence map›Paper›PMID 34050932›Full record

Observational studyClinical pharmacology and therapeutics2021

Association Between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: An Observational Multicenter Study.

Nicolas Hoertel, Marina Sánchez-Rico, Erich Gulbins, Johannes Kornhuber, Alexander Carpinteiro, Eric J Lenze, Angela M Reiersen, Miriam Abellán, Pedro de la Muela, Raphaël Vernet and 9 more

Open access · hybridAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical pharmacology and therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 68 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 4 countries.

Nicolas HoertelAssistance Publique-Hopitaux de Paris, DMU Psychiatrie et Addictologie, Hôpital Corentin-Celton, Institut de Psychiatrie et Neurosciences de Paris (IPNP), INSERM, UMR_S1266, Université de Paris, Paris, France.
Marina Sánchez-RicoAssistance Publique-Hopitaux de Paris, DMU Psychiatrie et Addictologie, Hôpital Corentin-Celton, Institut de Psychiatrie et Neurosciences de Paris (IPNP), INSERM, UMR_S1266, Université de Paris, Paris, France.
Erich GulbinsInstitute for Molecular Biology, University Medicine Essen, University of Duisburg-Essen, Essen, Germany.
Johannes KornhuberDepartment of Psychiatry and Psychotherapy, University Hospital, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
Alexander CarpinteiroInstitute for Molecular Biology, University Medicine Essen, University of Duisburg-Essen, Essen, Germany.
Eric J LenzeDepartment of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
Angela M ReiersenDepartment of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
Miriam AbellánAssistance Publique-Hopitaux de Paris, DMU Psychiatrie et Addictologie, Hôpital Corentin-Celton, Institut de Psychiatrie et Neurosciences de Paris (IPNP), INSERM, UMR_S1266, Université de Paris, Paris, France.
Pedro de la MuelaAssistance Publique-Hopitaux de Paris, DMU Psychiatrie et Addictologie, Hôpital Corentin-Celton, Institut de Psychiatrie et Neurosciences de Paris (IPNP), INSERM, UMR_S1266, Université de Paris, Paris, France.
Raphaël VernetMedical Informatics, Biostatistics and Public Health Department, Assistance Publique-Hopitaux de Paris, Centre-Université de Paris, Hôpital Européen Georges Pompidou, Paris, France.
Carlos BlancoDivision of Epidemiology, Services, and Prevention Research, National Institute on Drug Abuse, North Bethesda, Maryland, USA.
Céline CougouleInstitut de Pharmacologie et de Biologie Structurale, IPBS, Université de Toulouse, Toulouse, France.
Nathanaël BeekerUnité de Recherche clinique, Hopital Cochin, Assistance Publique-Hopitaux de Paris, Paris, France.
Antoine NeurazINSERM, UMR_S 1138, Cordeliers Research Center, Université de Paris, Paris, France.
Philip GorwoodINSERM, U1266 (Institute of Psychiatry and Neuroscience of Paris), Université de Paris, Paris, France.
Jesús M AlvaradoDepartment of Psychobiology and Behavioural Sciences Methods, Faculty of Psychology, Universidad Complutense de Madrid, Pozuelo de Alarcón, Madrid, Spain.
Pierre MenetonINSERM U1142 LIMICS, UMRS 1142, Sorbonne Universities, UPMC University of Paris 06, University of Paris 13, Paris, France.
Frédéric LimosinAssistance Publique-Hopitaux de Paris, DMU Psychiatrie et Addictologie, Hôpital Corentin-Celton, Institut de Psychiatrie et Neurosciences de Paris (IPNP), INSERM, UMR_S1266, Université de Paris, Paris, France.
AP-HP / Université de Paris / INSERM COVID-19 research collaboration, AP-HP COVID CDR Initiative, “Entrepôt de Données de Santé” AP-HP Consortium
Assistance Publique – Hôpitaux de Paris · FRUniversité Paris Cité · FRHôpital Corentin-Celton · FRWashington University in St. Louis · USComprehensive Cancer Center Erlangen · DEEssen University Hospital · DEInserm · FRInstitut de Psychiatrie et Neurosciences de Paris · FRNational Institute on Drug Abuse · USUniversidad Complutense de Madrid · ESUniversité de Toulouse · FRUniversity of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several medications commonly used for a number of medical conditions share a property of functional inhibition of acid sphingomyelinase (ASM), or FIASMA. Preclinical and clinical evidence suggest that the ASM/ceramide system may be central to severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection. We examined the potential usefulness of FIASMA use among patients hospitalized for severe coronavirus disease 2019 (COVID-19) in an observational multicenter study conducted at Greater Paris University hospitals. Of 2,846 adult patients hospitalized for severe COVID-19, 277 (9.7%) were taking an FIASMA medication at the time of their hospital admission. The primary end point was a composite of intubation and/or death. We compared this end point between patients taking vs. not taking an FIASMA medication in time-to-event analyses adjusted for sociodemographic characteristics and medical comorbidities. The primary analysis was a Cox regression model with inverse probability weighting (IPW). Over a mean follow-up of 9.2 days (SD = 12.5), the primary end point occurred in 104 patients (37.5%) receiving an FIASMA medication, and 1,060 patients (41.4%) who did not. Despite being significantly and substantially associated with older age and greater medical severity, FIASMA medication use was significantly associated with reduced likelihood of intubation or death in both crude (hazard ratio (HR) = 0.71, 95% confidence interval (CI) = 0.58-0.87, P < 0.001) and primary IPW (HR = 0.58, 95%CI = 0.46-0.72, P < 0.001) analyses. This association remained significant in multiple sensitivity analyses and was not specific to one particular FIASMA class or medication. These results show the potential importance of the ASM/ceramide system in COVID-19 and support the continuation of FIASMA medications in these patients. Double-blind controlled randomized clinical trials of these medications for COVID-19 are needed.

Indexed as

AdolescentAdultAgedAged, 80 and overCohort StudiesCOVID-19COVID-19 Drug TreatmentCOVID-19 TestingEnzyme InhibitorsFemaleHospitalizationHumansIntubation, IntratrachealMaleMiddle AgedMortalityEnzyme InhibitorsSMPD1 protein, humanSphingomyelin Phosphodiesterase

Identifiers

PMID34050932
PMCPMC8239599
OpenAlexW3165572635

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.